NASDAQ:ACAD - ACADIA Pharmaceuticals Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $28.29
  • Forecasted Upside: 59.95 %
  • Number of Analysts: 18
  • Breakdown:
  • 0 Sell Ratings
  • 13 Hold Ratings
  • 5 Buy Ratings
  • 0 Strong Buy Ratings
$17.69
▲ +0.09 (0.51%)

This chart shows the closing price for ACAD by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New ACADIA Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ACAD and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ACAD

Analyst Price Target is $28.29
▲ +59.95% Upside Potential
This price target is based on 18 analysts offering 12 month price targets for ACADIA Pharmaceuticals in the last 3 months. The average price target is $28.29, with a high forecast of $57.00 and a low forecast of $18.00. The average price target represents a 59.95% upside from the last price of $17.69.

This chart shows the closing price for ACAD for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 18 polled investment analysts is to hold stock in ACADIA Pharmaceuticals. This rating has held steady since February 2020, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 7 buy ratings
  • 10 hold ratings
  • 0 sell ratings
4/27/2020
  • 0 strong buy ratings
  • 7 buy ratings
  • 9 hold ratings
  • 0 sell ratings
7/26/2020
  • 0 strong buy ratings
  • 6 buy ratings
  • 10 hold ratings
  • 0 sell ratings
10/24/2020
  • 0 strong buy ratings
  • 6 buy ratings
  • 10 hold ratings
  • 0 sell ratings
1/22/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 12 hold ratings
  • 0 sell ratings
4/22/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 13 hold ratings
  • 0 sell ratings
7/21/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 13 hold ratings
  • 0 sell ratings
9/19/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 13 hold ratings
  • 0 sell ratings
10/19/2021

Latest Recommendations

  • 0 strong buy ratings
  • 5 buy ratings
  • 13 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
10/14/2021Morgan StanleyDowngradeOverweight ➝ Equal Weight$17.00 ➝ $20.00High
8/5/2021Needham & Company LLCLower Price TargetBuy$30.00 ➝ $26.00High
8/5/2021Morgan StanleyLower Price TargetOverweight$29.00 ➝ $27.00High
8/5/2021SVB LeerinkLower Price TargetOutperform$31.00 ➝ $28.00Medium
8/5/2021Cantor FitzgeraldLower Price TargetOverweight$33.00 ➝ $27.00Medium
7/19/2021SVB LeerinkReiterated RatingOutperformHigh
7/10/2021Raymond JamesSet Price Target$23.71Low
7/9/2021Raymond JamesReiterated RatingHoldLow
6/10/2021Berenberg BankInitiated CoverageHold$29.00High
5/12/2021Canaccord GenuityBoost Price TargetHold$26.00 ➝ $27.00High
5/6/2021Morgan StanleyBoost Price TargetOverweight$28.00 ➝ $29.00High
5/6/2021MizuhoReiterated RatingHoldHigh
4/13/2021The Goldman Sachs GroupReiterated RatingBuy ➝ Neutral$73.00 ➝ $25.00Low
4/13/2021Jefferies Financial GroupReiterated RatingBuy ➝ Hold$40.00 ➝ $21.00Low
4/13/2021MizuhoReiterated RatingBuy ➝ Neutral$25.00Low
4/13/2021Canaccord GenuityReiterated RatingBuy ➝ Hold$40.00 ➝ $26.00Low
4/13/2021HC WainwrightReiterated RatingBuy ➝ Neutral$43.00 ➝ $18.00N/A
4/7/2021HC WainwrightDowngradeBuy ➝ Neutral$43.00 ➝ $18.00Medium
4/6/2021SVB LeerinkLower Price TargetOutperform$63.00 ➝ $31.00Low
4/6/2021Morgan StanleyLower Price TargetOverweight$50.00 ➝ $28.00Low
4/6/2021Cantor FitzgeraldBoost Price TargetOverweight$33.00 ➝ $45.00Low
4/6/2021Canaccord GenuityDowngradeBuy ➝ Hold$40.00 ➝ $26.00Low
4/6/2021MizuhoDowngradeBuy ➝ Neutral$37.00 ➝ $25.00Low
4/6/2021Jefferies Financial GroupDowngradeBuy ➝ Hold$40.00 ➝ $21.00Low
4/5/2021The Goldman Sachs GroupDowngradeBuy ➝ Neutral$73.00 ➝ $25.00High
4/5/2021Raymond JamesDowngradeOutperform ➝ Market PerformHigh
4/5/2021Needham & Company LLCLower Price TargetBuy$44.00 ➝ $30.00High
3/16/2021Bank of AmericaReiterated RatingBuy ➝ NeutralHigh
3/15/2021Stifel NicolausReiterated RatingBuy ➝ Hold$68.00 ➝ $27.00N/A
3/15/2021Raymond JamesReiterated RatingStrong-Buy ➝ Outperform$65.00 ➝ $35.00N/A
3/15/2021GuggenheimReiterated RatingBuy ➝ NeutralN/A
3/15/2021CitigroupReiterated RatingBuy ➝ Neutral$66.00 ➝ $35.00N/A
3/10/2021Bank of AmericaDowngradeBuy ➝ NeutralHigh
3/9/2021GuggenheimDowngradeBuy ➝ NeutralHigh
3/9/2021Morgan StanleyLower Price TargetOverweight$65.00 ➝ $50.00High
3/9/2021CowenLower Price TargetOutperform$66.00 ➝ $57.00High
3/9/2021OppenheimerLower Price TargetMarket Perform$42.00 ➝ $28.00High
3/9/2021Canaccord GenuityLower Price TargetBuy$61.00 ➝ $40.00High
3/9/2021CitigroupDowngradeBuy ➝ Neutral$66.00 ➝ $35.00High
3/9/2021Needham & Company LLCLower Price TargetBuy$60.00 ➝ $44.00High
3/9/2021MizuhoLower Price TargetBuy$70.00 ➝ $55.00High
3/9/2021HC WainwrightLower Price TargetBuy$60.00 ➝ $43.00High
3/9/2021Royal Bank of CanadaLower Price TargetOutperform$60.00 ➝ $36.00High
3/9/2021Stifel NicolausDowngradeBuy ➝ Hold$68.00 ➝ $27.00High
3/9/2021Raymond JamesDowngradeStrong-Buy ➝ Outperform$65.00 ➝ $35.00High
3/2/2021Royal Bank of CanadaBoost Price TargetOutperform$55.00 ➝ $63.00High
2/25/2021Morgan StanleyBoost Price TargetOverweight$60.00 ➝ $65.00High
2/24/2021MizuhoReiterated RatingBuy$69.00 ➝ $70.00Medium
12/29/2020Cantor FitzgeraldReiterated RatingOverweight$61.00 ➝ $70.00N/A
12/16/2020Morgan StanleyBoost Price TargetOverweight$58.00 ➝ $60.00Low
12/15/2020MizuhoInitiated CoverageBuy$69.00Medium
11/16/2020Raymond JamesUpgradeOutperform ➝ Strong-Buy$65.00High
11/5/2020Morgan StanleyBoost Price TargetOverweight$57.00 ➝ $58.00Medium
10/13/2020Morgan StanleyBoost Price TargetOverweight$55.00 ➝ $57.00Low
8/24/2020Raymond JamesInitiated CoverageOutperform$65.00Low
8/20/2020Morgan StanleyInitiated CoverageOverweight$55.00Medium
8/6/2020HC WainwrightReiterated RatingBuyHigh
8/6/2020Needham & Company LLCReiterated RatingBuy$60.00Low
8/6/2020Canaccord GenuityBoost Price TargetBuy$56.00 ➝ $60.00Low
8/6/2020SVB LeerinkLower Price TargetOutperform$56.00 ➝ $52.00Medium
8/6/2020OppenheimerReiterated RatingHold$42.00Medium
7/28/2020Canaccord GenuityReiterated RatingHold$29.00Low
7/21/2020Jefferies Financial GroupReiterated RatingBuy$60.00High
7/21/2020CitigroupLower Price Target$69.00 ➝ $63.00High
7/21/2020Cantor FitzgeraldLower Price TargetOverweight$63.00 ➝ $61.00High
7/21/2020OppenheimerLower Price TargetPositive ➝ Market Perform$53.00 ➝ $42.00High
7/21/2020Royal Bank of CanadaLower Price TargetOutperform$61.00 ➝ $55.00High
7/16/2020Needham & Company LLCInitiated CoverageBuy$60.00Low
7/9/2020Royal Bank of CanadaBoost Price TargetPositive ➝ Outperform$58.00 ➝ $61.00Low
7/6/2020Stifel NicolausUpgradeHold ➝ Buy$41.00 ➝ $71.00High
5/27/2020OppenheimerBoost Price TargetMarket Perform$48.00 ➝ $53.00Medium
5/8/2020JPMorgan Chase & Co.Boost Price TargetOverweight$50.00 ➝ $55.00Medium
5/8/2020OppenheimerReiterated RatingHold$48.00High
5/8/2020Cantor FitzgeraldBoost Price TargetBuy$58.00 ➝ $63.00High
5/8/2020Needham & Company LLCReiterated RatingBuyHigh
4/16/2020Jefferies Financial GroupInitiated CoverageBuy$60.00Low
3/31/2020The Goldman Sachs GroupUpgradeNeutral ➝ Buy$45.00 ➝ $72.00High
3/5/2020CitigroupInitiated CoverageBuy$69.00High
3/5/2020CowenReiterated RatingBuy$66.00Medium
2/27/2020HC WainwrightReiterated RatingBuy$60.00High
2/27/2020Cantor FitzgeraldReiterated RatingOverweight$70.00 ➝ $75.00High
2/26/2020JPMorgan Chase & Co.Set Price TargetOutperform$50.00Medium
1/19/2020JPMorgan Chase & Co.Reiterated RatingBuyLow
1/14/2020CowenReiterated RatingBuy$66.00High
12/16/2019GuggenheimInitiated CoverageBuy$60.00High
12/5/2019HC WainwrightReiterated RatingBuy$60.00High
12/5/2019CowenReiterated RatingBuy$66.00High
11/27/2019JPMorgan Chase & Co.Reiterated RatingBuyLow
11/26/2019Cantor FitzgeraldBoost Price TargetOverweight$63.00 ➝ $70.00Low
11/26/2019CowenInitiated CoverageBuy$66.00Low
11/26/2019Royal Bank of CanadaReiterated RatingBuy$60.00Low
11/26/2019HC WainwrightReiterated RatingBuy$60.00Low
11/4/2019JPMorgan Chase & Co.Reiterated RatingBuy$50.00Low
11/1/2019HC WainwrightReiterated RatingBuy$60.00Medium
10/24/2019OppenheimerInitiated CoverageMarket Perform$44.00Medium
10/1/2019Royal Bank of CanadaInitiated CoverageOutperform$60.00Low
9/23/2019Cantor FitzgeraldBoost Price TargetOverweight$49.00 ➝ $56.00Low
9/13/2019SVB LeerinkUpgradeMarket Perform ➝ Outperform$21.00 ➝ $50.00Low
9/10/2019HC WainwrightSet Price TargetBuy$60.00Medium
9/10/2019JPMorgan Chase & Co.Reiterated RatingBuyHigh
9/10/2019Canaccord GenuityUpgradeHold ➝ Buy$29.00 ➝ $50.00High
9/9/2019Stifel NicolausSet Price TargetHold$39.00Medium
9/9/2019Piper Jaffray CompaniesBoost Price TargetOverweight$35.00 ➝ $56.00High
9/9/2019CowenReiterated RatingBuy$66.00Low
9/9/2019Needham & Company LLCBoost Price TargetBuy$34.00 ➝ $60.00High
9/3/2019Stifel NicolausBoost Price TargetHold$24.00 ➝ $28.00High
8/27/2019Cantor FitzgeraldReiterated RatingOverweight$30.00 ➝ $40.00Low
8/5/2019Needham & Company LLCReiterated RatingBuy$34.00Low
8/1/2019HC WainwrightReiterated RatingBuyLow
7/31/2019JPMorgan Chase & Co.Set Price TargetBuy$32.00N/A
7/31/2019Bank of AmericaSet Price TargetBuy$31.00N/A
7/23/2019Needham & Company LLCReiterated RatingBuy ➝ Buy$40.00 ➝ $34.00High
7/1/2019Needham & Company LLCReiterated RatingBuy$40.00Low
5/31/2019Raymond JamesBoost Price TargetStrong-Buy$40.00 ➝ $43.00Low
5/3/2019HC WainwrightReiterated RatingBuyHigh
5/2/2019JPMorgan Chase & Co.Reiterated RatingBuy$31.00High
4/25/2019Cantor FitzgeraldReiterated RatingBuy$30.00Medium
3/3/2019JPMorgan Chase & Co.Reiterated RatingBuyLow
2/28/2019Piper Jaffray CompaniesBoost Price TargetOverweight$30.00Low
2/27/2019Canaccord GenuityBoost Price TargetHold ➝ In-Line$23.00 ➝ $27.00High
2/27/2019Cantor FitzgeraldReiterated RatingBuy$30.00High
12/10/2018Canaccord GenuityInitiated CoverageHold ➝ Hold$23.00Medium
12/5/2018Cantor FitzgeraldReiterated RatingBuy$30.00Low
11/16/2018UBS GroupInitiated CoverageNeutral$39.00Low
11/12/2018SVB LeerinkInitiated CoverageMarket Perform$21.00High
11/7/2018Cantor FitzgeraldSet Price TargetBuy$30.00High
11/3/2018JPMorgan Chase & Co.Reiterated RatingBuyMedium
11/1/2018Cantor FitzgeraldBoost Price TargetOverweight ➝ Overweight$27.00 ➝ $30.00High
11/1/2018HC WainwrightReiterated RatingBuy$60.00High
10/31/2018Cantor FitzgeraldSet Price TargetBuy$27.00High
10/15/2018Cantor FitzgeraldBoost Price TargetOverweight ➝ Overweight$25.00 ➝ $27.00High
10/10/2018Bank of AmericaBoost Price TargetBuy ➝ Buy$22.00 ➝ $25.00High
10/2/2018Cantor FitzgeraldSet Price TargetBuy$25.00Medium
9/21/2018Piper Jaffray CompaniesInitiated CoveragePositiveHigh
9/20/2018Piper Jaffray CompaniesUpgradeNeutral ➝ Overweight$25.00High
9/20/2018Cantor FitzgeraldSet Price TargetBuy$25.00High
8/29/2018Cantor FitzgeraldReiterated RatingBuy$25.00Low
8/23/2018Cantor FitzgeraldInitiated CoverageOverweight$25.00High
8/9/2018JMP SecuritiesLower Price TargetMarket Outperform ➝ Market Outperform$50.00 ➝ $27.00High
8/9/2018HC WainwrightReiterated RatingBuy$60.00High
8/7/2018Stifel NicolausInitiated CoverageHold ➝ Hold$17.00Low
8/6/2018Piper Jaffray CompaniesDowngradeOverweight ➝ Neutral$19.00High
7/1/2018JPMorgan Chase & Co.Set Price TargetBuy$50.00Low
5/16/2018HC WainwrightReiterated RatingBuyMedium
4/10/2018JPMorgan Chase & Co.Set Price TargetBuy$50.00High
11/8/2017HC WainwrightReiterated RatingBuy$60.00N/A
11/7/2017CowenReiterated RatingBuy$46.00N/A
10/12/2017Jefferies Financial GroupReiterated RatingBuy$47.00N/A
10/9/2017SVB LeerinkReiterated RatingMarket PerformN/A
10/6/2017The Goldman Sachs GroupReiterated RatingNeutral$45.00N/A
10/5/2017JPMorgan Chase & Co.Set Price TargetBuy$50.00N/A
10/5/2017Piper Jaffray CompaniesReiterated RatingBuy$54.00 ➝ $61.00N/A
10/5/2017Bank of AmericaBoost Price TargetBuy ➝ Positive$40.00 ➝ $46.00N/A
10/5/2017JMP SecuritiesBoost Price TargetOutperform$47.00 ➝ $50.00N/A
10/5/2017HC WainwrightReiterated RatingBuy$60.00N/A
10/2/2017LADENBURG THALM/SH SHReiterated RatingBuy$48.00 ➝ $50.00Low
9/17/2017Needham & Company LLCReiterated RatingBuy$49.00Low
8/10/2017CowenReiterated RatingOutperform$42.00 ➝ $46.00High
8/9/2017Piper Jaffray CompaniesSet Price TargetBuy$54.00High
8/9/2017HC WainwrightReiterated RatingBuy$60.00High
5/22/2017Rodman & RenshawReiterated RatingBuy$60.00Low
5/10/2017HC WainwrightReiterated RatingBuyLow
4/12/2017Jefferies Financial GroupReiterated RatingBuy$47.00Low
4/5/2017Needham & Company LLCReiterated RatingBuy$49.00Low
3/3/2017HC WainwrightReiterated RatingBuy$60.00N/A
3/1/2017Needham & Company LLCReiterated RatingBuy$49.00N/A
2/7/2017Piper Jaffray CompaniesReiterated RatingOverweight$44.00N/A
2/2/2017LADENBURG THALM/SH SHInitiated CoverageBuy ➝ Buy$49.00 ➝ $48.00N/A
1/24/2017Needham & Company LLCReiterated RatingBuy$49.00N/A
1/24/2017CowenReiterated RatingOutperform$42.00N/A
1/14/2017CowenReiterated RatingOutperform$42.00N/A
1/11/2017JPMorgan Chase & Co.Reiterated RatingBuyN/A
12/28/2016SVB LeerinkReiterated RatingMarket Perform$29.00N/A
12/23/2016HC WainwrightReiterated RatingBuy$60.00N/A
12/23/2016Piper Jaffray CompaniesReiterated RatingOverweight$44.00N/A
12/23/2016Needham & Company LLCReiterated RatingBuy$49.00N/A
12/21/2016JPMorgan Chase & Co.Reiterated RatingOverweight$49.00N/A
11/11/2016The Goldman Sachs GroupInitiated CoverageNeutral$28.00N/A
11/10/2016CowenReiterated RatingOutperform$42.00N/A
11/8/2016SVB LeerinkReiterated RatingHold$29.00N/A
11/8/2016Bank of AmericaUpgradeNeutral ➝ Buy$35.00N/A
10/24/2016Needham & Company LLCReiterated RatingBuy$49.00N/A
(Data available from 10/20/2016 forward)

News Sentiment Rating

0.10 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/24/2021
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/23/2021
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/23/2021
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/22/2021
  • 2 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/22/2021
  • 1 very positive mentions
  • 8 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
8/21/2021
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
9/20/2021
  • 1 very positive mentions
  • 11 positive mentions
  • 4 negative mentions
  • 0 very negative mentions
10/20/2021

Current Sentiment

  • 1 very positive mentions
  • 11 positive mentions
  • 4 negative mentions
  • 0 very negative mentions
ACADIA Pharmaceuticals logo
ACADIA Pharmaceuticals, Inc. operates as a biopharmaceutical company. It focuses on the development and commercialization of medicines to address unmet medical needs in central nervous system, or CNS, disorders. The firm's products include Nuplazid, which is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The company was founded by Mark R. Brann on July 16, 1993 and is headquartered in San Diego, CA.
Read More

Today's Range

Now: $17.69
Low: $17.49
High: $17.88

50 Day Range

MA: $17.02
Low: $15.78
High: $18.49

52 Week Range

Now: $17.69
Low: $15.68
High: $57.46

Volume

692,227 shs

Average Volume

1,794,210 shs

Market Capitalization

$2.84 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.66

Frequently Asked Questions

What sell-side analysts currently cover shares of ACADIA Pharmaceuticals?

The following equities research analysts have issued stock ratings on ACADIA Pharmaceuticals in the last year: Bank of America Co., Berenberg Bank, Canaccord Genuity, Cantor Fitzgerald, Citigroup Inc., Cowen Inc, Guggenheim, HC Wainwright, Jefferies Financial Group Inc., Mizuho, Morgan Stanley, Needham & Company LLC, Oppenheimer Holdings Inc., Raymond James, Royal Bank of Canada, Stifel Nicolaus, SVB Leerink LLC, The Goldman Sachs Group, Inc., TheStreet, and Zacks Investment Research.
View the latest analyst ratings for ACAD.

What is the current price target for ACADIA Pharmaceuticals?

16 Wall Street analysts have set twelve-month price targets for ACADIA Pharmaceuticals in the last year. Their average twelve-month price target is $28.29, suggesting a possible upside of 59.9%. Cowen Inc has the highest price target set, predicting ACAD will reach $57.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $18.00 for ACADIA Pharmaceuticals in the next year.
View the latest price targets for ACAD.

What is the current consensus analyst rating for ACADIA Pharmaceuticals?

ACADIA Pharmaceuticals currently has 13 hold ratings and 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in ACAD, but not buy more shares or sell existing shares.
View the latest ratings for ACAD.

How do I contact ACADIA Pharmaceuticals' investor relations team?

ACADIA Pharmaceuticals' physical mailing address is 3611 VALLEY CENTRE DRIVE SUITE 300, SAN DIEGO CA, 92130. The biopharmaceutical company's listed phone number is (858) 558-2871 and its investor relations email address is [email protected] The official website for ACADIA Pharmaceuticals is www.acadia-pharm.com.